Does CYP3A4*1B change midazolam pharmacokinetics in preterm infants?

S. N. De Wildt, R. H.N. Van Schaik, D. J. Murry, N. M. Van Iperen, G. L. Kearns, J. N. Van Den Anker

Research output: Contribution to journalArticle

Abstract

The CYP3A4*1B mutation may be associated with altered CYP3A activity in adults. The CYP3A4 substrate midazolam (M) shows large interindividual PK differences in neonates. Thus, we studied the effect of CYP3A4*1B on M PK in preterm neonates. Methods: M (0.1 mg/kg) was administered as an oral bolus dose to 15 preterm infants (GA 26-34 wks, 3-13 days old, 11 Caucasians, 1 Mediterranean and 2 Caribbean Africans) followed by repeated blood sampling over 24 hrs. M and 1OHM concentrations were determined using GC-ELD; PK was determined with non compartmental analysis. CYP3A4*1B mutation analysis was carried out with PCR-RFLP. Results: M AUC0-∞ was significantly (p=0.043, Mann-Whitney test) lower in patients with the CYP3A4*1B genotype (1 A/G, 2 GG) compared to wildtype (12 A/A). M Cl/F (L/kg/h) was also increased, although not significantly (p=0.06) in the CYP3A4*1B carriers. Conclusions: The CYP3A4*1B appears to be associated with increased oral M clearance, which may reflect increased intestinal and/or hepatic CYP3A4 activity in preterm infants carrying the *1B allele.

Original languageEnglish (US)
Pages (from-to)P31
JournalClinical Pharmacology and Therapeutics
Volume69
Issue number2
StatePublished - Jan 1 2001

Fingerprint

Cytochrome P-450 CYP3A
Midazolam
Premature Infants
Pharmacokinetics
Newborn Infant
Mutation
Restriction Fragment Length Polymorphisms
Alleles
Genotype
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

De Wildt, S. N., Van Schaik, R. H. N., Murry, D. J., Van Iperen, N. M., Kearns, G. L., & Van Den Anker, J. N. (2001). Does CYP3A4*1B change midazolam pharmacokinetics in preterm infants? Clinical Pharmacology and Therapeutics, 69(2), P31.

Does CYP3A4*1B change midazolam pharmacokinetics in preterm infants? / De Wildt, S. N.; Van Schaik, R. H.N.; Murry, D. J.; Van Iperen, N. M.; Kearns, G. L.; Van Den Anker, J. N.

In: Clinical Pharmacology and Therapeutics, Vol. 69, No. 2, 01.01.2001, p. P31.

Research output: Contribution to journalArticle

De Wildt, SN, Van Schaik, RHN, Murry, DJ, Van Iperen, NM, Kearns, GL & Van Den Anker, JN 2001, 'Does CYP3A4*1B change midazolam pharmacokinetics in preterm infants?', Clinical Pharmacology and Therapeutics, vol. 69, no. 2, pp. P31.
De Wildt SN, Van Schaik RHN, Murry DJ, Van Iperen NM, Kearns GL, Van Den Anker JN. Does CYP3A4*1B change midazolam pharmacokinetics in preterm infants? Clinical Pharmacology and Therapeutics. 2001 Jan 1;69(2):P31.
De Wildt, S. N. ; Van Schaik, R. H.N. ; Murry, D. J. ; Van Iperen, N. M. ; Kearns, G. L. ; Van Den Anker, J. N. / Does CYP3A4*1B change midazolam pharmacokinetics in preterm infants?. In: Clinical Pharmacology and Therapeutics. 2001 ; Vol. 69, No. 2. pp. P31.
@article{4dd05f00497a46f49e37ceae8ff33297,
title = "Does CYP3A4*1B change midazolam pharmacokinetics in preterm infants?",
abstract = "The CYP3A4*1B mutation may be associated with altered CYP3A activity in adults. The CYP3A4 substrate midazolam (M) shows large interindividual PK differences in neonates. Thus, we studied the effect of CYP3A4*1B on M PK in preterm neonates. Methods: M (0.1 mg/kg) was administered as an oral bolus dose to 15 preterm infants (GA 26-34 wks, 3-13 days old, 11 Caucasians, 1 Mediterranean and 2 Caribbean Africans) followed by repeated blood sampling over 24 hrs. M and 1OHM concentrations were determined using GC-ELD; PK was determined with non compartmental analysis. CYP3A4*1B mutation analysis was carried out with PCR-RFLP. Results: M AUC0-∞ was significantly (p=0.043, Mann-Whitney test) lower in patients with the CYP3A4*1B genotype (1 A/G, 2 GG) compared to wildtype (12 A/A). M Cl/F (L/kg/h) was also increased, although not significantly (p=0.06) in the CYP3A4*1B carriers. Conclusions: The CYP3A4*1B appears to be associated with increased oral M clearance, which may reflect increased intestinal and/or hepatic CYP3A4 activity in preterm infants carrying the *1B allele.",
author = "{De Wildt}, {S. N.} and {Van Schaik}, {R. H.N.} and Murry, {D. J.} and {Van Iperen}, {N. M.} and Kearns, {G. L.} and {Van Den Anker}, {J. N.}",
year = "2001",
month = "1",
day = "1",
language = "English (US)",
volume = "69",
pages = "P31",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Does CYP3A4*1B change midazolam pharmacokinetics in preterm infants?

AU - De Wildt, S. N.

AU - Van Schaik, R. H.N.

AU - Murry, D. J.

AU - Van Iperen, N. M.

AU - Kearns, G. L.

AU - Van Den Anker, J. N.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - The CYP3A4*1B mutation may be associated with altered CYP3A activity in adults. The CYP3A4 substrate midazolam (M) shows large interindividual PK differences in neonates. Thus, we studied the effect of CYP3A4*1B on M PK in preterm neonates. Methods: M (0.1 mg/kg) was administered as an oral bolus dose to 15 preterm infants (GA 26-34 wks, 3-13 days old, 11 Caucasians, 1 Mediterranean and 2 Caribbean Africans) followed by repeated blood sampling over 24 hrs. M and 1OHM concentrations were determined using GC-ELD; PK was determined with non compartmental analysis. CYP3A4*1B mutation analysis was carried out with PCR-RFLP. Results: M AUC0-∞ was significantly (p=0.043, Mann-Whitney test) lower in patients with the CYP3A4*1B genotype (1 A/G, 2 GG) compared to wildtype (12 A/A). M Cl/F (L/kg/h) was also increased, although not significantly (p=0.06) in the CYP3A4*1B carriers. Conclusions: The CYP3A4*1B appears to be associated with increased oral M clearance, which may reflect increased intestinal and/or hepatic CYP3A4 activity in preterm infants carrying the *1B allele.

AB - The CYP3A4*1B mutation may be associated with altered CYP3A activity in adults. The CYP3A4 substrate midazolam (M) shows large interindividual PK differences in neonates. Thus, we studied the effect of CYP3A4*1B on M PK in preterm neonates. Methods: M (0.1 mg/kg) was administered as an oral bolus dose to 15 preterm infants (GA 26-34 wks, 3-13 days old, 11 Caucasians, 1 Mediterranean and 2 Caribbean Africans) followed by repeated blood sampling over 24 hrs. M and 1OHM concentrations were determined using GC-ELD; PK was determined with non compartmental analysis. CYP3A4*1B mutation analysis was carried out with PCR-RFLP. Results: M AUC0-∞ was significantly (p=0.043, Mann-Whitney test) lower in patients with the CYP3A4*1B genotype (1 A/G, 2 GG) compared to wildtype (12 A/A). M Cl/F (L/kg/h) was also increased, although not significantly (p=0.06) in the CYP3A4*1B carriers. Conclusions: The CYP3A4*1B appears to be associated with increased oral M clearance, which may reflect increased intestinal and/or hepatic CYP3A4 activity in preterm infants carrying the *1B allele.

UR - http://www.scopus.com/inward/record.url?scp=33748963096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748963096&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748963096

VL - 69

SP - P31

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 2

ER -